How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Buy
56
RGEN Quote, Financials, Valuation and Earnings
Last price:
$149.21
Seasonality move
:
8.03%
Day range:
$148.84 - $157.44
52-week range:
$102.97 - $175.77
Dividend yield:
0%
P/E ratio:
5,789.53x
P/S ratio:
11.90x
P/B ratio:
4.04x
Volume:
889.2K
Avg. volume:
605.4K
1-year change:
-10.84%
Market cap:
$8.4B
Revenue:
$634.4M
EPS (TTM):
$0.03
Analysts' Opinion
-
Consensus RatingRepligen Corp. has received a consensus rating of Buy. The company's average rating is a Buy based on 14 Buy ratings, 5 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $190.89, Repligen Corp. has an estimated upside of 27.8% from its current price of $149.37.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $160.00 representing 100% downside risk from its current price of $149.37.
Fair Value
-
According to the consensus of 19 analysts, Repligen Corp. has 27.8% upside to fair value with a price target of $190.89 per share.
RGEN vs. S&P 500
-
Over the past 5 trading days, Repligen Corp. has underperformed the S&P 500 by -8.29% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Repligen Corp. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Repligen Corp. has grown year-over-year revenues for 5 quarters straight. In the most recent quarter Repligen Corp. reported revenues of $188.8M.
Earnings Growth
-
Repligen Corp. has grown year-over-year earnings for 3 quarters straight. In the most recent quarter Repligen Corp. reported earnings per share of $0.26.
Enterprise value:
8.3B
EV / Invested capital:
--
Price / LTM sales:
11.90x
EV / EBIT:
178.69x
EV / Revenue:
11.79x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
80.68x
Price / Operating cash flow:
81.44x
Enterprise value / EBITDA:
48.85x
Gross Profit (TTM):
$331.3M
Return On Assets:
0.06%
Net Income Margin (TTM):
0.25%
Return On Equity:
0.09%
Return On Invested Capital:
0.06%
Operating Margin:
7.83%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $652.5M | $633.5M | $707.9M | $154.9M | $188.8M | |
| Gross Profit | $296.1M | $289.8M | $331.3M | $70.4M | $90.6M | |
| Operating Income | $63.7M | $27.8M | $46.7M | -$4.3M | $14.8M | |
| EBITDA | $139.5M | $116.5M | $170.9M | $17.2M | $49.1M | |
| Diluted EPS | $1.77 | -$0.15 | $0.03 | -$0.01 | $0.26 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $910.9M | $953.2M | $980.5M | $1.1B | $1.1B | |
| Total Assets | $2.2B | $2.5B | $2.5B | $2.8B | $2.9B | |
| Current Liabilities | $349.4M | $410.7M | $378.9M | $108.4M | $131.1M | |
| Total Liabilities | $526.1M | $627.4M | $549M | $814M | $840.6M | |
| Total Equity | $1.7B | $1.8B | $2B | $2B | $2.1B | |
| Total Debt | $308.2M | $405.4M | $416.6M | $660.3M | $669.6M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $146.7M | $165.3M | $130.9M | $49.3M | $48.1M | |
| Cash From Investing | -$74.7M | -$191.5M | -$154.5M | -$5.9M | -$7.8M | |
| Cash From Financing | -$19.4M | $183.8M | -$14M | -$69.6M | -$239K | |
| Free Cash Flow | $97.5M | $131.3M | $103.5M | $42.2M | $42.7M | |
RGEN
Sector
Market Cap
$8.4B
$24.3M
Price % of 52-Week High
84.98%
50%
Dividend Yield
0%
0%
Shareholder Yield
0.09%
-1.67%
1-Year Price Total Return
-10.84%
-21.43%
Beta (5-Year)
1.119
0.484
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$161.62
200-day SMA
Buy
Level
$138.83
Bollinger Bands (100)
Sell
Level
137.16 - 168.06
Chaikin Money Flow
Sell
Level
-779.6K
20-day SMA
Sell
Level
$164.31
Relative Strength Index (RSI14)
Sell
Level
31.92
ADX Line
Sell
Level
7.14
Williams %R
Buy
Level
-97.9639
50-day SMA
Sell
Level
$163.62
MACD (12, 26)
Buy
Level
11.92
25-day Aroon Oscillator
Sell
Level
-68
On Balance Volume
Sell
Level
-889.2K
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (6.5035)
Buy
CA Score
(Annual)
Level (0.5563)
Buy
Beneish M-Score
(Annual)
Level (-2.7705)
Buy
Momentum Score
Level (7)
Buy
Ohlson Score
Level (-2.7689)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (7)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. It operates through the North America. Europe, and Asia Pacific Region or Other geographical segments. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.
Stock Forecast FAQ
In the current month, RGEN has received 14 Buy ratings 5 Hold ratings, and 0 Sell ratings. The RGEN average analyst price target in the past 3 months is $190.89.
-
Where Will Repligen Corp. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Repligen Corp. share price will rise to $190.89 per share over the next 12 months.
-
What Do Analysts Say About Repligen Corp.?
Analysts are divided on their view about Repligen Corp. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Repligen Corp. is a Sell and believe this share price will drop from its current level to $160.00.
-
What Is Repligen Corp.'s Price Target?
The price target for Repligen Corp. over the next 1-year time period is forecast to be $190.89 according to 19 Wall Street analysts, 14 of them rate the stock a Buy, 0 rate the stock a Sell, and 5 analysts rate the stock a Hold.
-
Is RGEN A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Repligen Corp. is a Buy. 14 of 19 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of RGEN?
You can purchase shares of Repligen Corp. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Repligen Corp. shares.
-
What Is The Repligen Corp. Share Price Today?
Repligen Corp. was last trading at $149.21 per share. This represents the most recent stock quote for Repligen Corp.. Yesterday, Repligen Corp. closed at $149.37 per share.
-
How To Buy Repligen Corp. Stock Online?
In order to purchase Repligen Corp. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get RGEN Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
RGEN
Sector
P/E ratio
5,789.53x
23.33x
PEG ratio
0.00x
-0.01x
P/B ratio
4.04x
1.78x
Price / LTM sales
11.90x
1.53x
Growth Metrics
RGEN
Sector
Revenue growth
21.91%
4%
Earnings growth
2354.7%
11.06%
Revenue (5-year growth)
18.61%
6.22%
Earnings forecast
$0.44
-$0.19
Profitability
RGEN
Sector
Profitability FY 2024
$284M
$3M
Return on invested capital
0.06%
-33.25%
Return on assets
0.06%
-29.67%
Return on equity
0.09%
-38.89%
Earnings Date
Last Earnings Date
Oct
28
Next Earnings Date
Feb
17
Estimated Next Earnings Date
Jan
27
Balance Sheet
RGEN
Sector
Total cash
$748.7M
$25M
Short term investments
--
$24.9M
Total assets
$2.8B
$72.5M
Long term debt
$669.6M
$2.8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Sell
50
Is GOOGL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Alerts
Sell
40
GDXU alert for Jan 31
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 38.85% over the past day.
Sell
34
PFSI alert for Jan 31
PennyMac Financial Services, Inc. [PFSI] is down 33.21% over the past day.
Sell
40
SHNY alert for Jan 31
MicroSectors Gold 3X Leveraged ETN [SHNY] is down 31.56% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
